Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MRG-106 |
Synonyms | |
Therapy Description |
MRG-106 (cobomarsen) is an LNA-modified oligonucleotide that inhibits the microRNA miR-155-5p, which results in increased expression of miR-155-5p silenced genes and potentially leads to decreased proliferation and increased apoptosis of tumor cells (Blood 126.23 (2015): 3802, PMID: 30125933). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MRG-106 | Cobomarsen | MRG-106 (cobomarsen) is an LNA-modified oligonucleotide that inhibits the microRNA miR-155-5p, which results in increased expression of miR-155-5p silenced genes and potentially leads to decreased proliferation and increased apoptosis of tumor cells (Blood 126.23 (2015): 3802, PMID: 30125933). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT03713320 | Phase II | Vorinostat MRG-106 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR) | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT03837457 | Phase II | MRG-106 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM) | Terminated | USA | FRA | BEL | 0 |